Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

KalVista Pharmaceuticals (KALV) Equity Average (2017 - 2025)

KalVista Pharmaceuticals' Equity Average history spans 10 years, with the latest figure at $129.9 million for Q2 2025.

  • On a quarterly basis, Equity Average fell 12.0% to $129.9 million in Q2 2025 year-over-year; TTM through Apr 2025 was $129.9 million, a 12.0% decrease, with the full-year FY2025 number at $151.0 million, down 17.85% from a year prior.
  • Equity Average hit $129.9 million in Q2 2025 for KalVista Pharmaceuticals, down from $149.2 million in the prior quarter.
  • Over the last five years, Equity Average for KALV hit a ceiling of $209.1 million in Q2 2023 and a floor of $61.8 million in Q1 2021.
  • Historically, Equity Average has averaged $143.4 million across 4 years, with a median of $149.2 million in 2024.
  • The widest YoY moves for Equity Average: up 81.99% in 2021, down 34.12% in 2021.
  • Tracing KALV's Equity Average over 4 years: stood at $157.9 million in 2021, then decreased by 19.63% to $126.9 million in 2023, then rose by 17.56% to $149.2 million in 2024, then dropped by 12.94% to $129.9 million in 2025.
  • Business Quant data shows Equity Average for KALV at $129.9 million in Q2 2025, $149.2 million in Q4 2024, and $153.4 million in Q4 2024.